Literature DB >> 17173927

Human CD4+ regulatory T cells express lower levels of the IL-7 receptor alpha chain (CD127), allowing consistent identification and sorting of live cells.

Dennis J Hartigan-O'Connor1, Chungkee Poon, Elizabeth Sinclair, Joseph M McCune.   

Abstract

Although quantitative identification and viable enrichment of natural regulatory T cells (T-regs) in humans are problematic, such steps would greatly facilitate the analysis of these cells in disease states. In an attempt to identify markers that are sensitive and specific for human T-regs, we analyzed the expression of fourteen intracellular and cell surface markers on human CD4(+) cells. Many markers were partially selective for CD25(hi) T-regs, but consistent and specific discrimination of functional T-regs was only made possible by focus on CD127, the alpha chain of the IL-7 receptor. Although most CD4(+) human T cells express CD127, T-regs exhibiting suppressive activity in vitro display distinctly lower surface expression of this marker, irrespective of their level of CD25 expression. Sorted cells with the surface phenotype CD4(+)CD25(+)CD127(low) had higher levels of intracellular FOXP3 and CTLA-4 and, as determined by functional assays, were suppressive, hypoproliferative, and poorly responsive to TCR signaling. The CD4(+)CD25(+)CD127(low) phenotype was also found to be characteristic of T-regs found in mice and in rhesus macaques. This surface phenotype should allow for quantitative studies of regulatory T cells in disease states as well as for enrichment of live regulatory T cells for functional analyses and/or expansion in vitro.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17173927     DOI: 10.1016/j.jim.2006.10.008

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  107 in total

1.  CD4(+)CD25 (+)CD127 (low/-) T cells: a more specific Treg population in human peripheral blood.

Authors:  Ning Yu; Xiaomei Li; Weiya Song; Dongmei Li; Daliang Yu; Xiaofeng Zeng; Mengtao Li; Xiaomei Leng; Xiangpei Li
Journal:  Inflammation       Date:  2012-12       Impact factor: 4.092

2.  Effects of oral glucocorticoid therapy on CD4+CD25+CD127- and CD4+CD25high T cell levels in asthmatic patients.

Authors:  Marcin Moniuszko; Anna Bodzenta-Lukaszyk; Milena Dabrowska
Journal:  Inflammation       Date:  2010-12       Impact factor: 4.092

3.  SIV replication in the infected rhesus macaque is limited by the size of the preexisting TH17 cell compartment.

Authors:  Dennis J Hartigan-O'Connor; Kristina Abel; Koen K A Van Rompay; Bittoo Kanwar; Joseph M McCune
Journal:  Sci Transl Med       Date:  2012-05-30       Impact factor: 17.956

4.  Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone.

Authors:  Michael P Gustafson; Yi Lin; Kent C New; Peggy A Bulur; Brian Patrick O'Neill; Dennis A Gastineau; Allan B Dietz
Journal:  Neuro Oncol       Date:  2010-02-23       Impact factor: 12.300

5.  Reduced levels of both circulating CD4+ CD25+ CD127(low/neg) and CD4+ CD8(neg) invariant natural killer regulatory T cells in stable heart transplant recipients.

Authors:  M Chen; M Mohtize; M-F Matteï; J-P Villemot; C Kohler; G C Faure; M C Béné; M de Carvalho Bittencourt
Journal:  Clin Exp Immunol       Date:  2010-10-29       Impact factor: 4.330

Review 6.  Natural regulatory T cells and persistent viral infection.

Authors:  Shuo Li; Eric J Gowans; Claire Chougnet; Magdalena Plebanski; Ulf Dittmer
Journal:  J Virol       Date:  2007-09-12       Impact factor: 5.103

7.  Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients.

Authors:  Kimberly R Kalli; Matthew S Block; Pashtoon M Kasi; Courtney L Erskine; Timothy J Hobday; Allan Dietz; Douglas Padley; Michael P Gustafson; Barath Shreeder; Danell Puglisi-Knutson; Dan W Visscher; Toni K Mangskau; Glynn Wilson; Keith L Knutson
Journal:  Clin Cancer Res       Date:  2018-03-15       Impact factor: 12.531

8.  Immunomagnetic isolation of CD4+CD25+FoxP3+ natural T regulatory lymphocytes for clinical applications.

Authors:  M Di Ianni; B Del Papa; D Cecchini; E Bonifacio; L Moretti; T Zei; R Iacucci Ostini; F Falzetti; L Fontana; G Tagliapietra; C Maldini; M F Martelli; A Tabilio
Journal:  Clin Exp Immunol       Date:  2009-03-09       Impact factor: 4.330

9.  Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer.

Authors:  Stanimir Vuk-Pavlović; Peggy A Bulur; Yi Lin; Rui Qin; Carol L Szumlanski; Xinghua Zhao; Allan B Dietz
Journal:  Prostate       Date:  2010-03-01       Impact factor: 4.104

Review 10.  Rebuilding immunity in cancer patients.

Authors:  Stanimir Vuk-Pavlovic
Journal:  Blood Cells Mol Dis       Date:  2007-09-10       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.